Disease · MONDO_0021637
low grade glioma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. low grade glioma. Diseases, record MONDO_0021637. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021637
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 3 of its 50 drugs, from ClinicalTrials.gov, FDA and PMDA
- Open Targets
Drugs50
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TOVORAFENIB | CHEMBL3348923 | Small molecule | Approval | ClinicalTrials.gov and FDA | 7 | 6 | 6 | Drugs and targets |
| DABRAFENIB MESYLATE | CHEMBL2105729 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| TRAMETINIB DIMETHYL SULFOXIDE | CHEMBL2105741 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Phase 3 | ClinicalTrials.gov | 16 | 16 | 16 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| VINBLASTINE | CHEMBL159 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| VINCRISTINE | CHEMBL90555 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| LOMUSTINE | CHEMBL514 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| SELUMETINIB | CHEMBL1614701 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| PROCARBAZINE | CHEMBL1321 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 50
See all 50 drugsTargets50
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 7 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor | Approval | https://conductscience.org/library/genes/5604 | Drugs and targets |
| MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 2 | 7 | Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor | Approval | https://conductscience.org/library/genes/5605 | Drugs and targets |
| TUBA1A | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/112714 | Drugs and targets |
| TUBA4A | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7277 | Drugs and targets |
| TUBB | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/203068 | Drugs and targets |
| TUBB1 | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/81027 | Drugs and targets |
1 to 10 of 50
See all 50 targetsTrials75
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02034110 | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | Phase 2 | 206 | 2023-08-21 | Cancer | DABRAFENIB, TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02684058 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | Phase 2 | 151 | 2023-05-19 | Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Iponeurocytoma | DABRAFENIB, TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02124772 | Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations | Phase 1/2 | 139 | 2021-07-14 | Cancer | DABRAFENIB, TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00114140 | Temozolomide and Radiation Therapy in Treating Patients With Gliomas | Phase 2 | 136 | 2017-11-06 | Brain and Central Nervous System Tumors | TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00313729 | Temozolomide in Treating Patients With Low-Grade Glioma | Phase 2 | 120 | 2019-01-23 | CNS Tumor, Adult | TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02285439 | Study of MEK162 for Children With Low-Grade Gliomas | Phase 1/2 | 105 | 2025-10-07 | Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms | BINIMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00381797 | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma | Phase 2 | 97 | 2013-01-15 | Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma | BEVACIZUMAB, IRINOTECAN HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01677741 | A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | Phase 1/2 | 85 | 2021-11-24 | Neoplasms, Brain | DABRAFENIB | Its record names the disease | ClinicalTrials.gov |
| NCT00077207 | Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma | Not applicable | 66 | 2014-07-02 | Brain Tumor, Central Nervous System Tumor | CARBOPLATIN, TEMOZOLOMIDE, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT01734512 | PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children | Phase 2 | 65 | 2021-02-18 | Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 75
See all 75 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Astrocytoma vs Oligodendroglioma: Objective Response Rate | 0 of 32 | 0 of 32 | 64 | NCT00615927 | Trial comparisons |
| Astrocytoma vs Oligodendroglioma: serious adverse events | 10 of 32 | 3 of 32 | 64 | NCT00615927 | Trial comparisons |
| Phase II Stratum 1 vs Phase II Stratum 2: Best Overall Response Rate (Strata 1 and 2) | 15 of 27 | 12 of 21 | 48 | NCT02285439 | Trial comparisons |
| IMA950/Poly-ICLC Subcutaneous (subQ) + Varlilumab IV vs IMA950/Poly-ICLC subQ Only: deaths from any cause | 1 of 8 | 0 of 6 | 14 | NCT02924038 | Trial comparisons |
| IMA950/Poly-ICLC Subcutaneous (subQ) + Varlilumab IV vs IMA950/Poly-ICLC subQ Only: serious adverse events | 1 of 8 | 0 of 6 | 14 | NCT02924038 | Trial comparisons |
Papers from its trials53
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0021637
GET https://conductscience.org/api/diseases/v1/MONDO_0021637/drugs?page=2